Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tracon Pharmaceuticals Inc.
In addition to safety, this study will also evaluate pharmacokinetics, tumor response and anti-TRC105 antibody formation.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient has given informed consent.
The patient is willing and able to abide by the protocol.
The patient has cancer and curative therapy is unavailable.
The patient is at least 18 years old.
The patient has adequate ability to perform activities of daily living.
Significant toxicities from prior therapy must have recovered.
The patient has adequate organ function as assessed by laboratory test.
You may not be if
The patient weighs more than 264 lbs.
The patient has a known allergy to gentamicin
The patient has had prior treatment with high-dose chemotherapy requiring stem cell rescue
The patient is currently on treatment on another therapeutic clinical trial or has received an investigational agent within 4 weeks prior to first dose with study drug
The patient has had prior surgery (including open biopsy), radiation therapy or systemic therapy within 4 weeks of starting the study treatment
The patient has hypertension \> 160/90
The patient has a history of CNS cancer
The patient has an unstable medical condition including, but not limited to, cardiac disease, history of stroke, active hepatitis, or significant pericardial, pleural or peritoneal effusion
The patient received recent thrombolytic or anticoagulant therapy
The patient has lung cancer with central chest lesions
The patient has had hemorrhage or unhealed wounds within 30 days of dosing
The patient has used systemic corticosteroids within 3 months of dosing
The patient has known HIV/AIDS
The patient has a history of hypersensitivity reaction to human or mouse antibody products
The patient is pregnant or breastfeeding.
The patient has a history of peptic ulcer disease or gastritis within 6 months of dosing, unless complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 30 days of dosing
